A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies

Protocol No

ADICET-ADI-001-BCELL

Phase

I

Summary

Evaluate ADI-001 at different dose levels and in combination with Interleukin-2 (IL-2), an approved cancer treatment that helps your immune system fight cancers.

Description

A Phase 1 Study of ADI-001 in B Cell Malignancies

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL